Vaxart News and Activities

Vaxart is a company listed under the stock ticker VXRT (US).

Acquisition, funding and merger involving Vaxart.

• Vaxart has just announced a $453 Million fundraising (posted on June 15 2024).

View the org chart displaying its 23 main executives

Most searched biographies at Vaxart

• Steven Lo, President, Chief Executive Officer and Director
• David Wheadon, Director
• James Breitmeyer, Director

Popular executive movements at Vaxart

• James Breitmeyer has joined the company as Director  (posted on April 24 2026).
• Michael Finney, Chairman of the Board, will leave the company on Sep. 30, 2025  (posted on September 4 2025).

Create your alert
to follow the executive moves at Vaxart.

Vaxart has 2,405 competitors including Eurofins (Luxembourg), Lonza (Switzerland) and BioNTech (Germany).

Popular M&A news in Biotechnology

• IMU Biosciences has just announced a $53 Million fundraising (posted on June 3 2026).
• NewLimit has just announced a $435 Million fundraising (posted on June 3 2026).
• Rallybio and Avenzo Therapeutics have announced they will merge  (posted on June 1 2026)..

Popular contacts in Biotechnology

• Jakob Uszkoreit - Co-Founder and Chief Executive Officer at Inceptive
• Jan Van de Winkel - President and Chief Executive Officer at Genmab
• Valerie Hanote - Non-Executive Director at Eurofins

Learn more about the Biotechnology industry

Press releases by Vaxart

• Vaxart, Inc. –Vaxart Files Preliminary Proxy Statement and Issues Open Letter to Shareholders
• Vaxart, Inc. –Vaxart Provides Business Update and Reports First Quarter 2026 Financial Results
• Vaxart, Inc. –Vaxart to Host Stockholder Fireside Chat on May 8 at 4:30 p.m. ET
• Vaxart to Host Investor Q&A Webcast | Vaxart, Inc.
• Vaxart Announces Adjournment of Annual Meeting of Stockholders | Vaxart, Inc.
• New Preclinical Data Demonstrate Two of Vaxart’s COVID-19 Vaccine Candidates Protect Against Omicron | Vaxart, Inc.
• Vaxart to Participate at the Jefferies Global Healthcare Conference | Vaxart, Inc.
• Vaxart Reports Positive Preliminary Data from the Phase 1b Trial of its Oral Norovirus Vaccine Candidates in Elderly Adults | Vaxart, Inc.
• Vaxart Announces the Publication of Studies in the Peer-Reviewed Journal Science Translational Medicine That Suggest Mucosal Immunization Could Decrease SARS-CoV-2 Transmission | Vaxart, Inc.
• Vaxart Provides Business Update and Reports First Quarter 2022 Financial Results | Vaxart, Inc.
• View more press releases Close

Social media about Vaxart

• Vaxart on Wikipedia, Google News & Yahoo Finance
• Vaxart on LinkedIn, X (Twitter) & YouTube